Search

Your search keyword '"Chiche, Laurent"' showing total 624 results
Start Over Author "Chiche, Laurent" Publication Type Academic Journals
624 results on '"Chiche, Laurent"'

1. French protocol for the diagnosis and management of systemic lupus erythematosus

Author

Andre, Marc, Bienvenu, Boris, Blaison, Gilles, Blanco, Patrick, Cathebras, Pascal, Chauveau, Dominique, Chosidow, Olivier, Clouscard, Johanna, Deligny, Christophe, Duhaut, Pierre, Gobert, Pierre, Levesque, Hervé, Magy-Bertrand, Nadine, Melki, Isabelle, Pha, Micheline, Puechal, Xavier, Queyrel, Viviane, Raffray, Loïc, Ranchin, Bruno, Riviere, Marianne, Roblot, Pascal, Servettaz, Amelie, Amoura, Zahir, Bader-Meunier, Brigitte, Antignac, Marie, Bardin, Nathalie, Belizna, Cristina, Belot, Alexandre, Bonnotte, Bernard, Bouaziz, Jean-David, Chasset, François, Chiche, Laurent, Cohen, Fleur, Costedoat-Chalumeau, Nathalie, Daugas, Eric, Devilliers, Hervé, Diot, Elisabeth, Elefant, Elisabeth, Faguer, Stanislas, Ferreira, Nicole, Hachulla, Eric, Hanslik, Thomas, Hie, Miguel, Jourde-Chiche, Noémie, Le Guern, Véronique, Martin, Thierry, Mathian, Alexis, Michel, Marc, Miyara, Makoto, Papo, Thomas, Richez, Christophe, Scherlinger, Marc, Sibilia, Jean, Uzunhan, Yurdagul, Wahl, Denis, Wojtasik, Géraldine, and Yelnik, Cécile

Published
2024
Full Text
View/download PDF

6. Long-Term Outcome and Prognosis of Noninfectious Thoracic Aortitis

Author

Espitia, Olivier, Bruneval, Patrick, Assaraf, Morgane, Pouchot, Jacques, Liozon, Eric, de Boysson, Hubert, Gaudric, Julien, Chiche, Laurent, Achouh, Paul, Roussel, Jean-Christian, Miranda, Sébastien, Mirault, Tristan, Boussouar, Samia, Redheuil, Alban, Serfaty, Jean-Michel, Bénichou, Antoine, Agard, Christian, Guédon, Alexis F., Cacoub, Patrice, Paraf, François, Fouret, Pierre-Jean, Toquet, Claire, Biard, Lucie, and Saadoun, David

Published
2023
Full Text
View/download PDF

9. Thrombosis of Medium-Sized and Large Arteries During Covid-19 Infection: Results of the COVIVASC Study

Author

Coscas, Raphael, Dubosq, Maxime, Charton, Johanna, El Batti, Salma, Gaudric, Julien, Koskas, Fabien, Chiche, Laurent, Couture, Thibault, Davaine, Jean-Michel, Castier, Yves, Cerceau, Pierre, EL Hajjam, Mostafa, Samb, Patricia, Beauchet, Alain, Grimaldi, Lamiae, Javerliat, Isabelle, Goeau-Brissonniere, Olivier, Alsac, Jean-Marc, Onorati, Ilaria, Martinod, Emmanuel, Desgranges, Pascal, Touma, Joseph, Cochennec, Frédéric, Pellenc, Quentin, Julia, Pierre, and Coggia, Marc

Published
2022
Full Text
View/download PDF

22. Cardiovascular and connective tissue disorder features in FLNA-related PVNH patients: progress towards a refined delineation of this syndrome

Author

Billon, Clarisse, Adham, Salma, Hernandez Poblete, Natalia, Legrand, Anne, Frank, Michael, Chiche, Laurent, Zuily, Stephane, Benistan, Karelle, Savale, Laurent, Zaafrane-Khachnaoui, Khaoula, Brehin, Anne-Claire, Bal, Laurence, Busa, Tiffany, Fradin, Mélanie, Quelin, Chloé, Chesneau, Bertrand, Wahl, Denis, Fergelot, Patricia, Goizet, Cyril, Mirault, Tristan, Jeunemaitre, Xavier, and Albuisson, Juliette

Published
2021
Full Text
View/download PDF

23. Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data

Author

Altman, Matthew C., Rinchai, Darawan, Baldwin, Nicole, Toufiq, Mohammed, Whalen, Elizabeth, Garand, Mathieu, Syed Ahamed Kabeer, Basirudeen, Alfaki, Mohamed, Presnell, Scott R., Khaenam, Prasong, Ayllón-Benítez, Aaron, Mougin, Fleur, Thébault, Patricia, Chiche, Laurent, Jourde-Chiche, Noemie, Phillips, J. Theodore, Klintmalm, Goran, O’Garra, Anne, Berry, Matthew, Bloom, Chloe, Wilkinson, Robert J., Graham, Christine M., Lipman, Marc, Lertmemongkolchai, Ganjana, Bedognetti, Davide, Thiebaut, Rodolphe, Kheradmand, Farrah, Mejias, Asuncion, Ramilo, Octavio, Palucka, Karolina, Pascual, Virginia, Banchereau, Jacques, and Chaussabel, Damien

Published
2021
Full Text
View/download PDF

29. Protocol of supra-visceral aortic ischemic preconditioning for open surgical repair of thoracoabdominal aortic aneurysm: The EPICATA study (Evaluation of the Efficacy of Ischemic PreConditioning on morbidity and mortality in open ThoracoAbdominal Aortic surgery)

Author

Palmier, Mickael, Bubenheim, Mickael, Chiche, Laurent, Chaufour, Xavier, Koskas, Fabien, Fadel, Elie, Magnan, Pierre Edouard, Ducasse, Eric, Chakfe, Nabil, Steinmetz, Eric, Dusseaux, Marie Melody, Ricco, Jean Baptiste, and Plissonnier, Didier

Published
2020
Full Text
View/download PDF

30. Concordance and agreement between different activity scores in polymyalgia rheumatica.

Author

D'Agostino, Justine, Souki, Aghiles, Lohse, Anne, Alegria, Guillermo Carvajal, Dernis, Emanuelle, Richez, Christophe, Truchetet, Marie-Elise, Wendling, Daniel, Toussirot, Eric, Perdriger, Aleth, Gottenberg, Jacques-Eric, Felten, Renaud, Fautrel, Bruno, Chiche, Laurent, Hilliquin, Pascal, Le Henaff, Catherine, Dervieux, Benjamin, Direz, Guillaume, Chary-Valckenaere, Isabelle, and Cornec, Divi

Published
2024
Full Text
View/download PDF

32. Comparison of Immediate, Medium, and Long-Term Postoperative Results of Open Surgery and Fenestrated/Branched Stent Grafts for Extended Thoracoabdominal Aortic Aneurysms.

Author

Cochennec, Frédéric, Couture, Thibault, and Chiche, Laurent

Subjects
THORACOABDOMINAL aortic aneurysms, ABDOMINAL aortic aneurysms, ENDOVASCULAR surgery, ENDOVASCULAR aneurysm repair
Abstract

The optimal surgical treatment for extended thoracoabdominal aortic aneurysms (TAAAs) is still a matter of debate. The historical treatment is open repair (OR), but over the past fifteen years, endovascular strategies have gained widespread acceptance. Although several endovascular techniques have been described for the treatment of TAAAs, fenestrated and branched stent grafts (F/BEVARs) are the most frequently used and best documented. They have become the first-line treatment for both high- and moderate-risk surgical patients in most vascular centers. However, no randomized study comparing OR and F/BEVAR has been published, and decision-making is mainly based on the physician's preference and/or hospital expertise. The objective of this manuscript is to provide an overview of current comparative data for OR and F/BEVAR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Long-Term Outcome and Prognosis Factors of Isolated Aortitis

Author

Ferfar, Yasmina, Morinet, Sarah, Espitia, Olivier, Agard, Christian, Vautier, Mathieu, Comarmond, Chloé, Desbois, Anne Claire, Domont, Fanny, Fouret, Pierre Jean, Redheuil, Alban, Cluzel, Philippe, Chiche, Laurent, Koskas, Fabien, Resche-Rigon, Matthieu, Cacoub, Patrice, Biard, Lucie, and Saadoun, David

Published
2020
Full Text
View/download PDF

40. Complex relationships between inflammatory manifestations/type 1 and type 2 symptoms in systemic lupus erythematosus: A narrative literature review.

Author

Escoda, Thomas, Jourde-Chiche, Noémie, Granel, Brigitte, Cornec, Divi, and Chiche, Laurent

Subjects
LITERATURE reviews, SYSTEMIC lupus erythematosus, FIBROMYALGIA, FATIGUE (Physiology), QUALITY of life, SYMPTOMS
Abstract

Objective: Recent studies have highlighted that systemic lupus erythematosus (SLE) is characterized by different types of symptoms: type 1 symptoms related to inflammation and disease activity and type 2 symptoms such as fatigue, anxiety-depression, and pain. Our aim was to investigate the relation between type 1 and type 2 symptoms, and their impact on health-related quality of life (HRQoL) in SLE. Methods: A literature review was conducted about disease activity/type1 and type 2 symptoms. Articles in English published after 2000 were located on Medline via Pubmed. The articles chosen evaluated at least one type 2 symptom or HRQoL using a validated scale in adult patients. Results: Overall, 182 articles were analyzed and 115 were retained including 21 randomized, controlled trials and corresponding to 36 831 patients. We found that in SLE, inflammatory activity/type 1 symptoms were mostly uncorrelated with type 2 symptoms and/or HRQoL. Several studies even showing an inverse relationship. No or weak correlation was observed in 85, 3% (92, 6%), 76, 7% (74, 4%) and 37, 5% (73, 1%) of studies (patients) for fatigue, anxiety-depression, and pain, respectively. For HRQoL, no or weak correlation was observed in 77, 5% of studies (88% of patients). Conclusion: Type 2 symptoms are poorly correlated with inflammatory activity/type 1 symptoms in SLE. Possible explanations and implications for clinical care and therapeutic evaluation are discussed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Cytomegalovirus reactivation in ICU patients

Author

Papazian, Laurent, Hraiech, Sami, Lehingue, Samuel, Roch, Antoine, Chiche, Laurent, Wiramus, Sandrine, and Forel, Jean-Marie

Subjects
Bacterial pneumonia -- Health aspects, Antiviral agents -- Health aspects, Pneumonia -- Health aspects, Cytomegalovirus infections -- Health aspects, Epidemiology -- Health aspects, Hospital patients -- Health aspects, Acute respiratory distress syndrome -- Health aspects, Health care industry
Abstract

Introduction Approximately 20 years have passed since we reported our results of histologically proven cytomegalovirus (CMV) pneumonia in non-immunocompromised ICU patients. Even if there are more recent reports suggesting that CMV may worsen the outcomes for ICU patients, there is no definite answer to this question: is CMV a potential pathogen for ICU patients or is it simply a bystander? Methods We will describe the pathophysiology of active CMV infection and the most recent insights concerning the epidemiological aspects of these reactivations. Major findings Cytomegalovirus can be pathogenic by a direct organ insult (such as for the lung), by decreasing host defences against other microorganisms and/or by enhancing the body's inflammatory response (as in acute respiratory distress syndrome). The incidence of active CMV infection is dependent on the diagnostic method used. Using the most sophisticated available biological tools, the incidence can reach 15-20 % of ICU patients (20-40 % in ICU patients with positive CMV serology). In adequately powered cohorts of patients, active CMV infection appears to be associated with worse outcomes for mechanically ventilated ICU patients. Discussion There is no absolute direct proof of a negative impact of active CMV infection on the health outcomes of mechanically ventilated patients. Prospective randomized trials are lacking. Future trials should examine the potential benefits for health outcomes of using antiviral treatments. Such treatments could be prophylactic, pre-emptive or used only when there is an end-organ disease. Conclusion Cytomegalovirus infection may affect health outcomes for ICU patients. Additional prospective trials are necessary to confirm this hypothesis., Author(s): Laurent Papazian [sup.1] [sup.2], Sami Hraiech [sup.1] [sup.2], Samuel Lehingue [sup.1] [sup.2], Antoine Roch [sup.1] [sup.3], Laurent Chiche [sup.4], Sandrine Wiramus [sup.5], Jean-Marie Forel [sup.1] [sup.2] Author Affiliations: (1) [...]

Published
2016
Full Text
View/download PDF

48. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome

Author

Jasiek, Magali, Karras, Alexandre, Le Guern, Véronique, Krastinova, Evguenia, Mesbah, Rafik, Faguer, Stanislas, Jourde-Chiche, Noémie, Fauchais, Anne-Laure, Chiche, Laurent, Dernis, Emmanuelle, Moulis, Guillaume, Fraison, Jean-Baptiste, Lazaro, Estibaliz, Jullien, Perrine, Hachulla, Eric, Le Quellec, Alain, Rémy, Philippe, Hummel, Aurélie, Costedoat-Chalumeau, Nathalie, Ronco, Pierre, Vanhille, Philippe, Meas-Yedid, Vannary, Cordonnier, Carole, Ferlicot, Sophie, Daniel, Laurent, Seror, Raphaele, Mariette, Xavier, Thervet, Eric, François, Hélène, and Terrier, Benjamin

Published
2017
Full Text
View/download PDF

49. Anti-spike protein to determine SARS-CoV-2 antibody levels: Is there a specific threshold conferring protection in immunocompromised patients?

Author

Halfon, Philippe, Jordana, Sylvie, Blachier, Stéphane, Cartlamy, Philippe, Kbaier, Laurent, Psomas, Christina K., Philibert, Patrick, Antoniotti, Gilles, Allemand-Sourrieu, Julie, Rebaudet, Stanislas, Cavaille, Guilhem, Stavris, Chloé, Retornaz, Frédérique, Chiche, Laurent, and Penaranda, Guillaume

Subjects
IMMUNOCOMPROMISED patients, SARS-CoV-2, IMMUNOGLOBULINS, PRE-exposure prophylaxis, NEUTRALIZATION tests
Abstract

Background: Identifying a specific threshold level of SARS-CoV-2 antibodies that confers protection in immunocompromised patients has been very challenging. The aim was to assess the threshold of 264 binding antibody units (BAU)/ml using four different SARS-CoV-2 antibody assays (Abbott, Beckman, Roche, and Siemens) and to establish a new optimal threshold of protection for each of the four antibody assays. Methods: This study was performed on data retrieved from 69 individuals, who received at least one dose of the Pfizer/BioNTech BNT162b2 or Moderna COVID-19 vaccine (Spikevax) at the Alphabio Laboratory in Marseille, France (European Hospital, Alphabio–Biogroup). The results were compared to the percent inhibition calculated using a functional surrogate of a standardized virus neutralization test (Genscript). Results: Samples from 69 patients were analyzed. For a reference cutoff of 264 BAU/ml, assays showed moderate to good overall concordance with Genscript: 87% concordance for Abbott, 78% for Beckman, 75% for Roche, and 88% for Siemens. Overall concordance increased consistently after applying new thresholds, i.e., 148 BAU/ml (Abbott), 48 (Beckman), 559 (Roche), and 270 (Siemens). Conclusion: We suggest specific adjusted thresholds (BAU/ml) for the four commercial antibody assays that are used to assess pre-exposure prophylaxis in immunocompromised patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study.

Author

Peretti, Matthieu, Rebaudet, Stanislas, Chiche, Laurent, Pegliasco, Hervé, and Coquet, Emilie

Subjects
MEDICATION therapy management, AZITHROMYCIN, ELECTRONIC health records, COVID-19 pandemic, COVID-19, EMERGING infectious diseases
Abstract

Objectives: To evaluate the impact of local therapeutic recommendation updates made by the COVID multidisciplinary consultation meeting (RCP) at the Hôpital Européen Marseille (HEM) through the description of the drug prescriptions for COVID-19 during the first two waves of the epidemic. Methods: This retrospective observational study analysed data from the hospital's pharmaceutical file. We included all patients hospitalized for COVID-19 between February 1, 2020 and January 21, 2021 and extracted specific anti-COVID-19 therapies (ST) from computerized patient record, as well as patients' demographic characteristics, comorbidities and outcome. The evolution of ST prescriptions during the study period was described and put into perspective with the updates of local recommendations made during the first (V1, from 2/24/2020 to 7/27/2020), and second (V2, from 7/28/2020 to 1/21/2021) epidemic waves. Results: A total of 607 COVID-19 hospitalized patients, 197 during V1 and 410 during V2. Their mean age was 65 years-old, and they presented frequent comorbidities. In total, 93% of hospitalized patients received ST: anticoagulants (90%), glucocorticoids (39%) mainly during V2 (49% vs 17%, P<0.001), and azithromycin (30%) mainly during V1 (71% vs 10%, P<0.001). Lopinavir/ritonavir and hydroxychloroquine were prescribed to 17 and 7 inpatients, respectively, and only during V1. Remdesivir was never administered. A total of 22 inpatients were enrolled into clinical trials. Conclusions: The effective dissemination of evidence-based and concerted recommendations seems to have allowed an optimized management of COVID-19 drug therapies in the context of this emerging infection with rapidly evolving therapeutic questions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results